Literature DB >> 17326048

Catheter-related bloodstream infections in hematology: time for standardized surveillance?

Leon J Worth1, Monica A Slavin, Graham V Brown, James Black.   

Abstract

Central venous catheters are essential in the management of many malignant disorders, but catheter-related bloodstream infections (CR-BSIs) are significant complications in terms of morbidity, mortality, and healthcare expenditure. These outcome measures are useful for monitoring of infection control practice and the effect of preventive strategies. Unlike intensive care unit (ICU) populations, surveillance for CR-BSIs in the hematology population is not standardized, despite the potential value of detecting changes in rate, etiology, and changes in risk for infective complications in association with increasingly intensive chemotherapeutic regimens in this immunocompromised population. Essential components of a successful surveillance strategy include selection of a health outcome of significance, definition of goals of the surveillance system, involvement of key stakeholders in planning and development, application of valid case definitions, allocation of resources and trained personnel, risk stratification, and use of appropriate statistical methods for analysis. These are discussed with reference to patients with hematologic malignancy, together with review of previous surveillance strategies in this population. Only when these issues are addressed can a surveillance strategy reliably assess trends and compare data, leading to improved patient outcomes and a reduction in healthcare expenditure for patients with hematologic malignancy. (c) 2007 American Cancer Society.

Entities:  

Mesh:

Year:  2007        PMID: 17326048     DOI: 10.1002/cncr.22527

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Central line-associated bloodstream infections in adult hematology patients with febrile neutropenia: an evaluation of surveillance definitions using differential time to blood culture positivity.

Authors:  Joshua T Freeman; Anna Elinder-Camburn; Catherine McClymont; Deverick J Anderson; Mary Bilkey; Deborah A Williamson; Leanne Berkahn; Sally A Roberts
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-20       Impact factor: 3.254

2.  Infection Probability Score, APACHE II and KARNOFSKY scoring systems as predictors of bloodstream infection onset in hematology-oncology patients.

Authors:  Eleni Apostolopoulou; Vasilios Raftopoulos; Konstantinos Terzis; Ioannis Elefsiniotis
Journal:  BMC Infect Dis       Date:  2010-05-26       Impact factor: 3.090

3.  Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.

Authors:  Leon J Worth; John F Seymour; Monica A Slavin
Journal:  Support Care Cancer       Date:  2008-12-19       Impact factor: 3.603

4.  Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients.

Authors:  Salvatore Giacomo Morano; Lorenzo Coppola; Roberto Latagliata; Paola Berneschi; Antonio Chistolini; Alessandra Micozzi; Corrado Girmenia; Massimo Breccia; Gregorio Brunetti; Fulvio Massaro; Giovanni Rosa; Pietro Guerrisi; Franco Mandelli; Roberto Foà; Giuliana Alimena
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-02-14       Impact factor: 2.576

Review 5.  Surveillance of bloodstream infections in pediatric cancer centers - what have we learned and how do we move on?

Authors:  Arne Simon; Rhoikos Furtwängler; Norbert Graf; Hans Jürgen Laws; Sebastian Voigt; Brar Piening; Christine Geffers; Philipp Agyeman; Roland A Ammann
Journal:  GMS Hyg Infect Control       Date:  2016-05-12

6.  A case-control study to identify risk factors for totally implantable central venous port-related bloodstream infection.

Authors:  Guk Jin Lee; Sook Hee Hong; Sang Young Roh; Sa Rah Park; Myung Ah Lee; Hoo Geun Chun; Young Seon Hong; Jin Hyoung Kang; Sang Il Kim; Youn Jeong Kim; Ho Jong Chun; Jung Suk Oh
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.